Literature DB >> 3496099

Inhibition of cytochrome P-450-dependent oxidation reactions by MAO inhibitors in rat liver microsomes.

H Dupont, D S Davies, M Strolin-Benedetti.   

Abstract

The inhibition of cytochrome P-450 dependent hydroxylations of bufuralol (BH) and antipyrine, and O-deethylation of 7-ethoxycoumarin (7-ECOD) by several monoamine oxidase inhibitors (MAOIs) was investigated in rat liver microsomes. According to their IC50 values, clorgyline was the most potent inhibitor while toloxatone, the only reversible MAOI in this study, was the least potent. A great variability of inhibitory potencies was found, even in the same chemical class of MAOIs. Irreversible inhibition of BH and 7-ECOD has been studied. Rapid irreversible inhibition occurred in some cases, and this could be responsible for in vivo inhibition after repeated dosing of these MAOIs.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3496099     DOI： 10.1016/0006-2952(87)90050-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


  9 in total

Review 1.  Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review.

Authors:  G B Baker; R T Coutts; K F McKenna; R L Sherry-McKenna
Journal:  J Psychiatry Neurosci       Date:  1992-11       Impact factor: 6.186

2.  An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.

Authors:  Thomas M Polasek; David J Elliot; Andrew A Somogyi; Elizabeth M J Gillam; Benjamin C Lewis; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

3.  Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.

Authors:  Joo-Youn Cho; Kyung-Sang Yu; In-Jin Jang; Byung-Hwan Yang; Sang-Goo Shin; Dong-Seok Yim
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

Review 5.  Metabolism of monoamine oxidase inhibitors.

Authors:  G B Baker; L J Urichuk; K F McKenna; S H Kennedy
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

6.  The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors.

Authors:  R Alemany; G Olmos; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

7.  Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.

Authors:  Mahnaz Salsali; Andrew Holt; Glen B Baker
Journal:  Cell Mol Neurobiol       Date:  2004-02       Impact factor: 5.046

8.  Differences between monoamine oxidase concentrations in striatum and forebrain of aged and young rats.

Authors:  Y Arai; H Kinemuchi
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

9.  Repeated treatment with furazolidone induces multiple cytochrome p450-related activities in chicken liver, but not in rat liver.

Authors:  Nobuo Sasaki; Tomoyuki Matumoto; Yoshinori Ikenaka; Shouta M M Nakayama; Mayumi Ishizuka; Akio Kazusaka; Shoichi Fujita
Journal:  J Vet Med Sci       Date:  2013-06-18       Impact factor: 1.267
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.